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Abstract
Cystic fibrosis is a frequent autosomal recessive disorder that is caused by the malfunctioning of a small chloride channel, the
cystic fibrosis transmembrane conductance regulator. The protein is found in the apical membrane of epithelial cells lining
exocrine glands. Absence of this channel results in imbalance of ion concentrations across the cell membrane. As a result, fluids
secreted through these glands become more viscous and, in the end, ducts become plugged and atrophic. Little is known about
the pathways that link the malfunctioning of the CFTR protein with the observed clinical phenotype. Moreover, there is no strict
correlation between specific CFTR mutations and the CF phenotype. This might be explained by the fact that environmental and
additional genetic factors may influence the phenotype. The CFTR protein itself is regulated at the maturational level by
chaperones and SNARE proteins and at the functional level by several protein kinases. Moreover, CFTR functions also as a
regulator of other ion channels and of intracellular membrane transport processes. In order to be able to function as a protein
with pleiotropic actions, CFTR seems to be linked with other proteins and with the cytoskeleton through interaction with PDZ-
domain-containing proteins at the apical pole of the cell. Progress in cystic fibrosis research is substantial, but still leaves many
questions unanswered.  2002 European Cystic Fibrosis Society. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
A poem dating from the 18th century ‘The child will
soon die whose brow tastes salty when kissed’ already
referred to cystic fibrosis (CF). The elevated sweat salt
concentration became the prime characteristic for the
diagnosis of CF in the middle of the 20th century. In
1938, the clinical features associated with CF focused
on abnormal functioning of the pancreas and the disease
was called ‘cystic fibrosis of the pancreas’ w1x. Later
on, however, other mucus secreting glands like the
intestinal epithelium, the intrahepatic bile ducts, the gall
bladder and the lung were found to contribute to the
disease phenotype w2x. In a hot summer, CF babies
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responded adversely to heat during periods of high
atmospheric temperature w3x and had elevated sweat salt
concentrations w4x. This finding indicated that not only
mucus-secreting glands were involved and therefore the
more general terms ‘cystic fibrosis’ or ‘mucoviscidosis’
were introduced. The study of CF families revealed that
this frequent disease, one in 2500 newborns in the
Caucasian population is affected, is inherited in an
autosomal recessive way w2x. The gene defective in
cystic fibrosis, the Cystic Fibrosis Transmembrane Con-
ductance Regulator (CFTR) gene, was identified in
1989 w5–7x. This gene encodes a small conductance
ATP- and cAMP-dependent chloride channel that is
found at the apical border of epithelial cells lining most
exocrine glands. Seventy percent of the affected genes
carry a 3-bp deletion, F508del, but a worldwide survey
has increased the number of CF causing mutations
located in the CFTR gene up to more than 900 w8x.
Since then, attention has focused on how these mutations
cause abnormal functioning of the chloride channel; and
on the biogenesis and working mechanism of CFTR.
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Current therapies can only increase the quality of life,
and the lifespan, of CF-patients and much more research
will be indispensable in the search for a final cure.
2. Phenotypes associated with cystic fibrosis
Not all CF-patients show the same clinical picture,
even when they carry identical mutations. Although
pancreas malfunctioning is strongly correlated w9x, the
severity and progress of lung disease is only very weakly
correlated with the CFTR genotype. This points to the
existence of other genetic andyor environmental factors
that influence the effect of the CFTR defect on the
disease phenotype in an organ-dependent way w10x.
Some polymorphisms that modify the lung phenotype
have already been identified. They are predominantly
located in genes involved in host defense and inflam-
mation w11x. Polymorphisms that result in high levels
of TNFa, or in low levels of glutathione S-transferase
M1 w12x or of mannose binding lectin w13x have been
associated with more severe lung disease in CF patients.
Polymorphisms that result in a1-antitrypsin deficiency
w14x or a1-antichymotrypsin deficiency w15x are asso-
ciated with less severe pulmonary disease. The codon
10 polymorphism of TGF-b1, which causes higher
production of TGF-b1, is associated with a more rapid
detoriation of lung function w16x. The risk of coloniza-
tion with Pseudomonas aeruginosa is increased in
patients carrying the HLA class II DR7 allele w17x and
in patients that have autoantibodies to the bactericidaly
permeability increasing protein w18x.
The majority of CF-patients have a sweat chloride
concentration higher than 60 meq.yl, an abnormality
that is the basis for the principal diagnostic test for
cystic fibrosis. CFTR is present in the apical and
basolateral membranes of cells lining the sweat duct
and is necessary for the reabsorption of sweat chloride
ions secreted by the sweat coil. This process is driven
by the absorption of Na ions through Na channelsq q
present in the apical membrane of the sweat duct. When
CFTR is absent, or malfunctioning, the reabsorption
process will be inefficient and, as a result, up to five
times higher sweat chloride concentrations are found in
patients from birth on w19x. Some CF-patients, however,
clearly show a CF phenotype but exhibit normal or
borderline sweat chloride concentrations. This results
often in a delayed or missed diagnosis of cystic fibrosis
w20,21x. Alternative diagnostic tests needed therefore to
be developed. Altered intestinal currents in rectal biop-
sies and altered nasal potentials as well as failure to
release ATP in response to deformation w22x or in
response to cAMP induction in the presence of the
MRP1yMDR1 blockers tamoxifen or cyclosporine w23x,
are currently being evaluated as new diagnostic tests.
According to the pancreatic status of the patients, CF
mutations can be subdivided into two groups, mild and
severe mutations w9x. Until recently, it was assumed that
severe mutations resulted in a CFTR protein with very
low, or no, chloride transport activity. Some mutations
associated with pancreatic insufficiency show, however,
normal or even increased chloride conductance w24x.
Measurement of the HCO secretion associated withy3
the different mutations pointed out that CFTR channels
with severe mutations do not support HCO transport,y3
although some of them exhibit normal or even increased
chloride conductance. Mutations found in pancreatic
sufficient patients are associated with reduced, but still
measurable, HCO secretion w25x. This secreted bicar-y3
bonate normally acts to neutralize the acidic stomach
fluid in the gut such that digestive enzymes can operate
at their optimal pH. Since this is not the case in severe
CF-patients, the intake of additional pancreatic enzyme
supplements is necessary in order to ensure sufficient
energy uptake. The reduced CFTR activity also causes
reduced water content of the pancreatic secretions,
resulting in precipitation of proteins, and plugging and
fibrosis of the ductules and acini w26x. As a result,
pancreatic enzymes are unable to move to the gut and
the pancreas undergoes autodigestion. Many patients
with severe disease eventually also develop diabetes.
Although most CF-infants are born with unaffected
lungs, lung disease forms the most life-threatening
feature of cystic fibrosis. CFTR chloride channels pres-
ent in lung epithelium ensure the secretion of chloride
ions and, as a consequence, of water, in the airway fluid
such that the mucus secretions are easily cleared from
the airways. In CF airway epithelia, however, chloride
secretion is decreased and sodium absorption is
increased w27,28x. As a consequence, the secreted mucus
is fairly dry and rigid and very difficult to clear w19x.
The affected lung epithelium also shows an increased
inflammatory response, probably due to reduced concen-
trations of the anti-inflammatory factor IL10 w29x and
to an increased breakdown, most probably by neutrophil
elastase, of the anti-inflammatory protein annexin 1
present in the bronchoalveolar lavage fluid w30x. As a
result, CF lungs become chronically colonized with
pathogens like Pseudomonas aeruginosa, Staphylococ-
cus aureus, Burkholderia cepacia, «, and develop
increased inflammatory responses which result in even
more rigid mucus and bronchiectasis that in the end will
lead to death by cardiac failure. Cystic fibrosis patients
also show enhanced sensitivity to Pseudomonas aeru-
ginosa. Different theories have been proposed to explain
this. First, the composition of the secreted proteoglycans
is changed; the quantity of asialo-proteoglycans, which
result in a better adherence of Pseudomonas aeruginosa,
is increased w31x. Second, the altered ion composition
of the airway fluid inactivates secreted human beta
defensin 1 and 2, naturally occurring antibiotic peptides
that form part of the primary protection mechanism of
the lung against bacterial infections w32x. Third, CFTR
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acts as a receptor for the lipopolysaccharide (LPS) chain
of Pseudomonas aeruginosa. Binding of CFTR to this
LPS chain results in endocytosis and degradation of the
pathogen. In cystic fibrosis cells, however, the CFTR
protein is often absent in the apical membrane and, as
a consequence, cannot participate in the clearance of
Pseudomonas aeruginosa w33x. Although most of these
theories need further proof, integration of these different
hypotheses may result in a better explanation of the
complicated phenotype observed in the airways of cystic
fibrosis patients.
Liver cirrhosis complicates CF in 1–2% of the
patients. CFTR is localized in the epithelial cells lining
the biliary ductules that transport bile to the gall bladder.
The secretion of chloride ions, and as a consequence of
water, into this duct is necessary to keep bile acids and
proteins soluble in the bile fluid. Absence or malfunc-
tioning presumably results in ductules plugged with
secretions leading to liver cirrhosis w19x.
In the gut, reduced water secretion leads to meconium
ileus in 10–15% of CF new-borns. Later on in life,
meconium ileus equivalent can occur due to malfunc-
tioning of the pancreas and of intestinal mucosal glands.
Most female CF-patients are fertile or show only a
slightly reduced fertility due to decreased water content
of the cervical mucus, a feature that may hinder sperm
penetration. Ninety-seven percent of CF-males, however,
are infertile due to congenital bilateral absence of the
vas deferens (CBAVD) w34x. Since the vas deferens is
present in fetuses with CF, it is likely that the duct
becomes obstructed at a later age and eventually atro-
phies. How this occlusion of the vas occurs and how it
is related to CFTR malfunctioning, is not known yet
w35x.
Although the disease phenotype associated with cystic
fibrosis is very severe, the frequency of CF-carriers in
the Caucasian population is very high: 1 in 25 people
carry one CFTR mutation. A selective advantage for
CF-carriers has been proposed and multiple hypotheses
exist such as an increased resistance to Vibrio cholera
infections w36x and to typhoid fever w37x.
3. CFTR: from gene to protein
The CFTR gene is located on the long arm of
chromosome 7 (7q31), spans 250 kb of genomic DNA
and contains 27 exons w38x. After transcription, a 6.1-
kb transcript is generally obtained. Different tissue and
time-specific transcription start sites are found. Since
the CFTR promoter has the characteristics of a house-
keeping promoter, the use of different transcription start
sites can impose a regulation on gene expression that
explains the time and tissue-specific expression pattern
seen for CFTR w39x. Alternatively, the production of
functional CFTR proteins can be influenced by tissue
and time-specific alternative splicing. Different alterna-
tively spliced forms of CFTR have been detected: exon
4 w40x, exon 5 w41x, exon 9 w42,43x, insertion ofy y y
119 bp of intron 10 w44x, exon 12 w45x and TRN-y
CFTR w46x. The exon 5 splice variant is exclusivelyy
expressed in the heart; its functional relevance remains,
however, unclear w41x. The percentage of non-functional
exon 9 -CFTR can vary between tissues: it is higher iny
the vas deferens than in nasal epithelium w42,43x. Over-
expression of splicing factors, like hnRNP A1 and ASFy
SF2, can modulate this exon 9 skipping of alleles
carrying the T5yT7yT9 polymorphism w47x. TRN-CFTR
is a kidney-specific alternatively spliced form of CFTR
that, as a result of the introduction of a premature
stopcodon, gives rise to a protein that only contains the
N-terminal part of CFTR (the first transmembrane
region, the first nucleotide binding domain and the
regulatory domain). It is characterized by ‘wildtype’
single channel characteristics but it incorporates less
efficiently in the cell membrane. The expression of this
TRN-CFTR in the kidney is cell type and time-specific,
it gradually replaces the full-length protein during devel-
opment w48x. These examples indicate that alternative
splicing provides a way to regulate CFTR expression
andyor function.
The CFTR gene encodes a 1480-amino acid long
transmembrane protein with a symmetrical structure
(Fig. 1): a repeat composed of a transmembrane region
(TMD) containing six transmembrane helices (TM) and
a nucleotide binding domain (NBD), separated by a
large hydrophilic regulatory (R) domain. These features
are characteristic for a large family of ATP-Binding
Cassette Transporters (ABC transporters) found in
eukaryotes and prokaryotes; the R domain, however, is
unique for CFTR. During co-translational transport
through the Sec 61-translocon, the CFTR polypeptide is
integrated in the endoplasmic reticulum (ER) membrane
and is N-glycosylated through addition of two core
glycosylation groups on its fourth extracellular loop
(Fig. 2). In this way, the molecular weight of the CFTR
protein increases from 130 to 150 kDa. With the aid of
chaperone molecules, such as calnexin and Hsp70, the
polypeptide is correctly folded, becomes protease resis-
tant and is transported to the Golgi-stacks. In this last
compartment, the glycosylation groups are further mod-
ified to form a mature protein of 170 kDa. It is this last
form that will be transported to the cell membrane of
CFTR expressing cells where it can function as a
chloride channel w49x. Once present in the cell
membrane, CFTR undergoes cycles of endocytosis
through clathrin-coated vesicles and recycling back to
the cell membrane w50x. The C-terminal tail of CFTR
contains a tyrosine based internalization signal (sur-
rounding Y1424). Mutation of this tyrosine to alanine
reduces endocytosis by 40% w51x and prevents binding
of the AP-2 adaptor complex w52x. This recycling
process is regulated by cAMP such that an increase in
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Fig. 1. Schematic representation of the CFTR chloride channel. The different domains, transmembrane domain 1 (TMD1) and 2 (TMD2),
nucleotide binding domain 1 (NBD1) and 2 (NBD2), the regulatory domain (R), the N-terminal (NH ) and C-terminal (COOH) ends, the PKA2
(arrowhead) and PKC (arrowhead and underlined) consensus sites and the glycosylation sites present on the fourth extracellular loop are indicated.
cAMP results in a net increase in the amount of CFTR
proteins present in the cell membrane w53x. The mature
protein has a half-life of 16 h and is ultimately recruited
from the cell membrane to be targeted to the lysosomes
for degradation w49x.
The folding process in the ER is apparently very
inefficient: only 25% of the produced translation prod-
ucts attain a protease resistant form that allows transport
to the Golgi-stacks. The remainder is not able to fold
into its protease resistant form and is degraded in an
ubiquitin-dependent pathway by the cytosolic 26S pro-
teasome complex. The 26S proteasome is a protein
degradation complex composed of different proteases
and ATPases. It recognizes and degrades proteins car-
rying large chains of ubiquitin and is important for the
degradation of misfolded proteins, proteins involved in
cell cycle control, transcriptional regulation and signal
transduction, and for the processing of antigens which
will be presented as peptides by the MHC class I
pathway w54x. The link between CFTR degradation and
maturation is formed by chaperone molecules. Hsc70
interacts specifically with the immature B-form of
CFTR. The co-chaperone CHIP contains a TRP motif
necessary for interaction with Hsc70 and a U-box motif
found in the E4 family of polyubiquination factors and
it interacts with proteasome subunits. Overexpression of
CHIP results in increased ubiquination of CFTR indi-
cating that the CHIP–Hsc70 complex targets misfolded
CFTR to ubiquitin conjugating enzymes w55x. The deg-
radation of ubiquinated proteins occurs in the cytoplasm.
Transport of ubiquinated CFTR from the ER to the
cytosol is therefore necessary. This occurs through the
Sec61-translocon and during this process CFTR poly-
peptides are bound by the b-subunit of the translocon
complex. They are deglycosylated and in the end are
degraded by the cytosolic proteasome w56x. It has been
shown that CFTR polypeptides are ubiquinated, even
before translation is complete. This might indicate that
ubiquitin plays an important role in the biogenesis of
CFTR and the equilibrium between de-ubiquination by
ubiquitin isopeptidases and ubiquitin chain elongation
may determine the ultimate faith of the protein: matu-
ration through the Golgi-stacks or degradation by the
proteasome complex w57x. Moreover, since the level of
CHIP expression determines the amount of ubiquinated,
and as a consequence degraded, CFTR, cell-specific
differences in CHIP expression might result in a cell
type-specific distribution of CFTR at the cell membrane
w55x.
Regulation of CFTR-expression is thus very complex
at both the transcriptional level by the initiation of
transcription, the position of transcription start sites and
the formation of alternatively spliced transcripts, and at
the (post)-translational level where the equilibrium
between protein maturation and degradation is deter-
mined by at least two factors, ubiquination and the
action of different chaperones.
4. The CFTR protein functions as a chloride channel
CFTR is an ATPaseyABC-transporter that functions
as a chloride channel that is characterized by a small
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Fig. 2. Maturation model of wildtype and F508del CFTR. Both wild-
type and F508del CFTR enter the endoplasmic reticulum during co-
translational transport processes. Wildtype CFTR then folds, with the
aid of chaperone molecules, such as calnexin and Hsp70-CHIP, into
a protease resistant form that is able to leave the ER and will further
mature in the Golgi-stacks before it reaches the cell surface. Once
present at the cell membrane, the protein is recycled through cycles
of endo- and exocytosis. The protein is ultimately degraded in lyso-
somes. The majority of wildtype translation products, and almost all
F508del CFTR, is not able to fold into the protease resistant form in
the ER and will be degraded by cytosolic proteasomes.
Fig. 3. Model of CFTR channel gating (modified from Gadsby and
Nairn w57x). Activation of the CFTR chloride channel starts with
phosphorylation of the R domain by protein kinase A. When CFTR
is only partially phosphorylated, only the first nucleotide-binding
domain will be able to bind and hydrolyze ATP resulting in only brief
openings of the chloride channel. When the R domain is fully phos-
phorylated, binding and hydrolysis of ATP by NBD1 will not only
result in opening of the channel but also in binding of ATP at NBD2.
In this way, a stabilization of the open state is achieved and long
openings of the channel will be observed. When, in a next step, ATP
is hydrolyzed at NBD2 and the hydrolyzation products are released
at both NBDs, the channel will close. However, as long as the R
domain is phosphorylated the cycles of binding and hydrolysis of ATP,
and as a consequence, of opening and closing of the channel, can go
on. Once the R domain is dephosphorylated by phosphatases, the
channel will close and phosphorylation of the R domain by PKA will
be necessary in order to activate the channel again. Activated NBDs
are lined.
conductance (7–10 pS) and a linear current–voltage
relationship. It is selective for anions over cations and
exhibits the following anion permeability sequence:
Br )Cl )I )F . The regulation of the CFTR chlo-y y y y
ride channel is very complex. Multiple kinases can
activate the CFTR chloride channel but only protein
kinase A-dependent activation of CFTR has been
described in detail. A simplified model is given in Fig.
3 w57x. First the R domain is phosphorylated by cAMP-
dependent protein kinase A (PKA). This allows binding
of ATP to nucleotide binding domain 1. When ATP is
hydrolyzed by NBD1, the channel opens and anions can
flow, according to the electrochemical gradient, through
the pore formed by the transmembrane domains. When
the R domain is fully phosphorylated, the second nucle-
otide-binding domain can bind ATP. This event stabilizes
the open state of the chloride channel and results in
longer openings. When in a next step ATP is hydrolyzed
at NBD2 and ADP and Pi are released from both NBDs,
the channel will close again w58x. As long as the R
domain is phosphorylated, the cycles of binding and
hydrolysis of ATP at both nucleotide binding domains
can continue and, as a consequence, the opening and
closing of the channel. However, when the R domain is
dephosphorylated by phosphatases (for example PP2A
and PP2C w59,60x), the NBDs are not able anymore to
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bind ATP and the channel will stay in the closed state
until the R domain is rephosphorylated by PKA.
Experiments performed to elucidate the function of
the different domains, and the way in which they
communicate with each other, indicate that the CFTR
chloride channel is characterized by a very complex and
sensitive regulation, not only at the domain but also at
the interdomain level. Moreover, accumulating data
indicate that CFTR can form dimers resulting in a
chloride channel with altered electrophysiological char-
acteristics; hereby increasing the complexity of chloride
channel regulation w61–63x.
4.1. The regulatory domain
The exact boundaries of this domain remain a point
of discussion. Initially the R-domain was defined as that
part of the CFTR protein encoded by exon 13. Compar-
ison of R-domains derived from different species indi-
cated that the N-terminal part, up to amino acid 650, is
highly conserved and mutations located in this part
result in a processing defect w24x. These studies indicate
that this N-terminal part of exon 13 belongs to NBD1,
a domain with a strict folding pattern, and not to the R
domain w64x.
The C-terminal end of the R-domain is less conserved
and contains most of the PKA and PKC phosphorylation
sites (Fig. 1). Since the identification of the CFTR gene,
the unraveling of the physiological stimulation pathway
of the CFTR chloride channel has been focused on
activation by PKA, through cAMP. Later on, however,
it was found that cyclic GMP-dependent protein kinases
(PKG) are also able to activate CFTR. Both PKGI and
II are able to phosphorylate, in vitro, the CFTR R
domain at sites that largely overlap with the PKA
phosphorylation sites. However, only PKGII is able to
phosphorylate CFTR in vivo, and membrane targeting
of PKGII is required w65–68x. The PKGII pathway,
which uses cGMP instead of cAMP, is stimulated by
the hormone guanylin and results in activation of CFTR
in the intestinal epithelium and the pancreas, hereby
regulating intestinal and pancreatic electrolyte secretion
w69x. Phosphorylation of CFTR by the calciumycalmo-
dulin-dependent protein kinase I has been detected in
vitro w70x and PKC only slightly activates the channel
but it enhances the activation by PKA w71x. The C-
terminal end (amino acids 780–830) can be replaced
by the MDR1 linker domain without affecting the PKA
stimulated chloride transport. Both fragments have the
same length and posses an equal amount, and more or
less equal spreading, of PKA consensus sites. This
indicates that the precise sequence of the C-terminal end
of the R domain is not that important for activation, but
only the presence of PKA consensus sites w72x.
The stimulatory effect of phosphorylation can be
mimicked by mutagenesis of the different PKA sites to
aspartate, an amino acid with a net negative charge, or
by deleting that part of the R domain where the majority
of the PKA sites are located (amino acids 760–830).
Both approaches result in a permanently open channel.
This could indicate that the R domain forms, in its
unphosphorylated state, a plug that closes the pore of
the chloride channel. Phosphorylation introduces nega-
tive charges into this domain, an action that is mimicked
in the aspartate mutant, which results in repulsion of the
‘plug’ from the pore of the channel and, as a conse-
quence, in opening of the channel w73x.
Deletion of the R domain, however, results in a
chloride channel that is only partially active, when
compared with the wildtype CFTR channel in its acti-
vated state. Addition of phosphorylated R domain pep-
tides to this deletion mutant doubles the channels open
probability. How this activation occurs is far from
understood w73x. Structural analysis of the R-domain
indicates that the peptide encompassing amino acids
708–831 is rather unstructured: 5% helical structures
and the remaining has a random coil configuration.
Phosphorylation of this peptide does not change the
conformation. It is, however, possible that phosphory-
lation of the R domain present in the intact CFTR
protein results in a small structural alteration or in
interaction with other CFTR domains like the nucleotide
binding domains w74x. Most probably, the conformation-
al changes increase the affinity of NBD1 for ATP.
Although the R domain seems to be unstructured,
activating and inhibitory domains could be identified.
Deletion of amino acids 760–783 is necessary to pro-
duce a constitutive open chloride channel indicating that
these amino acids are necessary to keep the channel
closed in the unphosphorylated state. Deletion of the
region 817–838, which contains charged residues,
results in a chloride channel that is insensitive for PKA,
suggesting that this domain is required for stimulation
w73x.
Phosphorylation of one single PKA consensus site in
the C-terminal part of the R domain seems to be
sufficient to activate the channel w75x. Recent mutage-
nesis experiments indicate that the different phosphory-
lation sites have a different but site-specific contribution,
which can be either activatory or inhibitory, for the
activation state of the chloride channel. Since the con-
tribution of the different sites is additive, a fine-tuning
of the activation state of the chloride channel can be
achieved by phosphorylation of a specific combination
of PKA sites. The higher the activation state, the better
nucleotide-binding domain 1 can interact with ATP
w76,77x. The activation state of the R domain determines
also the stability of the open state of the CFTR chloride
channel by interfering with the binding of nucleotides
to nucleotide binding domain 2; once ATP is bound at
NBD1, a non-hydrolysable ATP analogue (AMP-PNP)
is only able to lock CFTR in its open state, and as a
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consequence to bind to NBD2, when the CFTR channel
exhibits a high open probability, which means a high
degree of R domain phosphorylation w78x. A high degree
of communication thus exists between the R domain
and the nucleotide binding domains. The exact nature
of these interactions remains, however, far from
understood.
4.2. The nucleotide binding domains
Both nucleotide binding domains show only 29%
overall amino acid homology but contain motifs neces-
sary for ATP binding and hydrolysis: the Walker A
motif (GXXGXGKTyS), the Walker B motif (Ry
KX h D) and the linker region (LSGGQ) (where X7–8 4
refers to any amino acid and h to a hydrophobic residue).
After activation of the CFTR chloride channel by PKA,
ATP binding and hydrolysis at NBD1 can occur and, as
a consequence, channel activity is initiated. Binding of
ATP at NBD2, however, increases this activation state
but subsequent ATP hydrolysis at NBD2 terminates
channel activity. For this fine-tuning of channel activity,
an interaction between both nucleotide-binding domains
seems necessary w79x. Intracellular ATP concentrations
have to be 5 mM minimal (i.e. the physiological
concentration in the cell), before ATP hydrolysis at
NBD1 and, as a consequence, ion gating can occur. In
this way the nucleotide binding domains seem to act as
energy sensors that protect the cell against excessive
energy depletion through excessive electrolyte transport
w80x.
4.3. The transmembrane domains
The transmembrane domains contain transmembrane
helices that form the pore of the channel. Here for the
first and sixth transmembrane helices of TMD1 seem to
interact with TMD2 w81x.
Scanning-cysteine-accessibility analysis pointed out
that amino acids residing in the first, third and sixth
transmembrane helix take part in the formation of the
ion pore w82x. Moreover, residues located in the region
of amino acids 351 and 353 seem to determine the
anion–cation selectivity w83x and residue T338 seems
to play an important, but rather indirect role in the
determination of the permeation properties of the CFTR
chloride channel w84x.
Expression of a polypeptide containing only the first
transmembrane domain is sufficient to produce a chlo-
ride channel that is constitutively active and that is
characterized by an almost ‘wildtype’ single channel
conductance. This indicates that this domain contains
all the information necessary to form a chloride channel
that escapes regulation by ATP and cAMP w85x. In
wildtype CFTR, however, the pore can only be opened
after phosphorylation of the R domain and ATP hydrol-
ysis by the first nucleotide-binding domain and will
only close after ATP hydrolysis at NBD2. This implies
that the transmembrane domains have to interact with
the cytosolic domains. This hypothesis was sustained by
mutagenesis studies that indicated that the different
cytoplasmic loops, which connect the transmembrane
helices within TMD1 and TMD2, interact with the
nucleotide binding domains w86–90x. Further studies
are, however, required to unravel the nature of the
interactions between these domains.
5. CFTR is more than a chloride channel
5.1. CFTR inhibits the amiloride sensitive epithelial
sodium channel
The airways of cystic fibrosis patients are character-
ized by a dehydrated mucus layer not only due to
decreased chloride secretion but also to increased sodium
absorption through the amiloride sensitive epithelial
sodium channel (ENaC) present in lung epithelial cells
w91x. The link between both transport processes is
thought to be played by CFTR itself w92,93x. In the
absence of CFTR, cAMP increases the absorptive activ-
ity of rENaC by increasing its open probability. When
CFTR is present, however, stimulation by cAMP results
in a decrease in open probability of the sodium channel,
hereby decreasing the absorption of sodium ions across
the epithelium w94x. This down-regulation of rENaC is
not observed when the most common CFTR mutant
F508del, or the non-conductive G551D variant are
present; an observation that is in agreement with the
high sodium absorption found in CF lung epithelia w95x.
The amiloride sensitive epithelial sodium channel is
composed of three subunits (a,b and g). Contradictory
data exist about the nature of its interaction with CFTR.
Using the yeast two-hybrid system, a direct interaction
between a CFTR polypeptide, containing NBD1 and the
R domain of CFTR, and the carboxyterminal part of the
a-subunit of rENaC has been detected w96x. Ismailov et
al. w97x found by incorporation of CFTR and rENaC in
lipid bilayers that the interaction was dependent on the
presence of actin: small actin filaments increased the
inhibitory effect of CFTR on rENaC. Functional inter-
actions between CFTR and the regulatory parts of
rENaC, i.e. b andyor g, and between actin and the a-
subunit of rENaC were required. A third study pointed
out that the amino termini of in vitro translated a and
b-rENaC were able to immunoprecipitate CFTR. Co-
expression of CFTR and rENaC in oocytes resulted in
a two-way regulation: CFTR down-regulates rENaC and
this down-regulation increases when CFTR is activated
by PKA, and rENaC in turn is able to up-regulate CFTR
sixfold in this expression system. This up-regulation is
independent of cytoplasmic Na concentrations orq
membrane potential and is partially due to an increased
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amount of CFTR proteins in the cell membrane; the
effect of CFTR on ENaC on the other hand requires
intracellular Cl . Both interactions require the carbox-y
yterminus of b-rENaC. The down-regulation of rENaC
by unstimulated CFTR requires both the carboxytermi-
nus of b-rENaC and the aminoterminus of g-rENaC
w98x. Taken together, it seems that there is a lot of
discrepancy between the different studies. Moreover,
most of them were performed using overexpression of
rat ENaC and not the human variant. Study of endoge-
nous human ENaC and CFTR in the sweat duct showed
that activation of CFTR results in a stimulation of Naq
transport through ENaC, and not a down-regulation as
described above for the heterologous expression systems
w99x. This might indicate that the regulation of ENaC
by CFTR is tissue-specific and might require modulating
cell-specific factors. Therefore, studies using rat ENaC
and over-expression of CFTR and ENaC in cells not
expressing these proteins endogenously, should be inter-
preted carefully.
5.2. CFTR activates the outwardly rectifying chloride
channel
Before the identification of the CFTR gene, the defect
in chloride transport found in CF epithelia was not
assigned to the malfunctioning of a small linear chloride
channel, like CFTR, but to the malfunctioning of the
outwardly rectifying chloride channel (ORCC) w100x.
This channel indeed malfunctions in cystic fibrosis cells
due to a defect in its regulation by PKA w101x. This
regulation is dependent on the presence of nucleotide
binding domain 1 and the regulatory domain of CFTR
w85x and seems to occur via phosphorylation of the
CFTR R domain w101x. Moreover, extracellular ATP is
needed to activate ORCC. It is believed that activation
of CFTR triggers the transport of ATP out of the cell,
which will then activate the ORCC through a P puri-2u
nergic receptor-dependent signaling mechanism, a
hypothesis that awaits further proof w102x. The CFTR
sequences essential for Cl transport and activation ofy
ORCC seem to be different: A455E and G551D are two
CFTR mutations resulting in CFTR channels with
reduced chloride transport but A455E retains its ability
to stimulate ORCC and not G551d. A455E is associated
with mild lung disease, G551D with severe, pointing to
the importance of the regulatory properties of CFTR
w103x.
5.3. CFTR activates an associated ATP channel
Contradictory data exist about the ability of CFTR to
transport ATP w104–107x, but recent findings indicate
that the permeation pathways for Cl and ATP arey
distinct and that the ATP conduction pathway is not
obligatorily associated with CFTR expression; findings
that indicate that CFTR is able to regulate an associated
but distinct ATP channel. The stimulation of this ATP
channel is CFTR-dependent since nucleotide hydrolysis
by and phosphorylation of CFTR regulates the activity
of the ATP channel w108x.
Non-CF cells respond to hypotonic stress by the
release of ATP, through a distinct ATP channel. This
ATP binds to a purinergic receptor resulting in the
activation of chloride transport and reduction of the cell
volume. This feature is called regulatory volume
decrease. When CFTR is absent or mutated to F508del,
cells fail to release ATP in response to deformation and
show reduced regulatory volume decrease w22x.
Whether both studies describe the same ATP channel
or whether multiple ATP channels are involved remains
unknown.
5.4. CFTR sensitizes potassium channels to sulfonylurea
compounds
The renal potassium channel ROMK2 is only slightly
inhibited by glibenclamide, while the inwardly rectifying
K channel Kir6.1 is not inhibited at all by thisq
sulfonylurea compound. When intact CFTR proteins are
present, however, the sensitivity of both potassium
channels to glibenclamide is enhanced w109,110x. Co-
expression studies indicate that even a truncated form
of CFTR, containing only the N-terminal part including
an intact NBD1 of CFTR, was able to impose this
enhanced sensitivity to ROMK2. Moreover, absence of,
or mutations within, the first nucleotide-binding domain
of CFTR reduced the regulatory activities of CFTR.
This indicates that CFTR with an intact NBD1 is able
to regulate the sensitivity of another channel, ROMK2,
to the inhibitory compound glibenclamide w111x.
5.5. CFTR inhibits volume-regulated anion channels
Many cell types react upon cell swelling by the
induction of chloride currents through volume-regulated
anion channels. The molecular identity of these channels
remains unknown. They are characterized by specific
pharmacological and electrophysiological properties.
When COS cells or CPAE cells (bovine pulmonary
artery endothelium) were transfected with CFTR, the
swelling induced chloride currents were inhibited and
this inhibition was independent of the activation status
of CFTR w112x.
5.6. CFTR inhibits endogenous calcium-activated chlo-
ride currents
Bovine pulmonary artery endothelium cells express
endogenous Ca activated chloride (CaCC) currents.2q
Transfection of these cells with CFTR resulted in down-
regulation of CaCC that even increased upon stimulation
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of CFTR by forskolin. The CFTR variant F508del did
not have any effect on CaCC w113x.
5.7. CFTR alters the activity of multiple ion channels
endogenously expressed in Xenopus laevis oocytes
CFTR is also able to regulate multiple channels
endogenously expressed in Xenopus laevis oocytes: it
inhibits calcium activated chloride conductances w114x,
and activates chromanol-inhibitable potassium conduc-
tances w115x. It also enhances, after stimulation by
cAMP, the osmotic water permeability of oocytes. This
occurs through activation of aquaporin 3 w116x.
5.8. CFTR alters the ion composition of intracellular
compartments
CFTR is not only present in the cell membrane where
it transports chloride ions and small neutral amino acids
w117x and regulates other ion channels, it is also present
in intracellular membranes. Chloride transport through
CFTR in intracellular compartments like the Golgi-
network, prelysosomes and endosomes is important
since it creates a driving force for subsequent acidifica-
tion of these organelles, a process that is important for
glycosylation and ligand traffic. In CF cells an alkali-
zation of these cell compartments is observed, resulting
in the production of glycoproteins with an altered
glycosylation pattern: sialylation is reduced and sulfation
is increased w118,119x. Pseudomonas aeruginosa, a CF
airway colonizing bacterium, attaches preferentially to
asialo-glycoproteins. As a consequence, the malfunction-
ing of CFTR could increase the colonization of CF
airways by pathogens.
5.9. CFTR regulates intracellular vesicle transport
Cell surface CFTR is constitutively internalized via
clathrin-coated vesicles, possibly through an interaction
with the adaptor complex AP-2 w52x, and recycled back
to the membrane through exocytosis w53x. Stimulation
of protein phosphorylation by cAMP results in an
increase in the amount of chloride channels present in
the cell membrane due to an arrest of membrane
endocytosis and stimulation of exocytosis. The cAMP
induced increase in whole cell current is therefore not
only due to the activation of CFTR channels present in
the cell membrane but also due to the recruitment of
vesicular CFTR proteins w120–122x. Moreover, depend-
ent on the content of the vesicles, the number of CFTR
channels in the cell membrane will increase, and in
addition, other channels, which are present in these
vesicles, will also increase. This could explain the link
between activation of CFTR and its cAMP-dependent
regulation of other channels, a hypothesis that needs
further proof w123x. The mechanism regulating the
cAMP-dependent protein recycling is not very clear.
CFTR itself seems to play an important role since
endocytosis is not inhibited by cAMP when a non-
functional CFTR variant, like G551D CFTR, is present
in the cell membrane w53x. The cytoskeleton is also
important and an intact vesicle transporting machinery
is required w124x. When the microtubule network is
disrupted by nocodazole, the forskolin induced increase
in the number of CFTR proteins present in the cell
membrane is prevented. Incubation with cytochalasin D,
a disrupter of actin microfilaments, however, has no
effect, indicating that actin microfilaments are not
important for the cAMP-dependent trafficking of CFTR
w125x. cAMP stimulation of chloride transport is, how-
ever, accompanied by a reorganization of actin filaments
on the basal side of the cell. This reorganization is
necessary since fixation of actin filaments by NBD-
phallocidin inhibits cAMP-dependent chloride transport
w126x. The relation between both cAMP stimulated
processes remains unclear and different hypotheses have
been proposed. First, actin stimulates apical chloride
transport indirectly by the formation of a driving force
for chloride movement through activation of the baso-
lateral Na yK y2Cl co-transporter w127x. Second,q q y
small actin filaments activate CFTR in a direct way
w128x. Third, a direct activation of CFTR by small actin
filaments was not observed but degradation of actin
filaments by cytochalasin D resulted in activation of the
channel, indicating that cytochalasin D might activate
CFTR by releasing a cellular inhibitor, like a phospha-
tase, that is held in place by F-actin w129x. All these
hypotheses await, however, further proof.
6. CFTR and its intracellular neighbors
CFTR is itself prone to regulation by protein kinase
A and seems to be able to regulate the activity of a
whole series of other channels. Recently, some insight
has been gained into the complex network that surrounds
CFTR, at the cell membrane, and that allows cross-talk
between different proteins (Fig. 4). It is clear that other,
and potentially more important, interacting proteins will
be identified in the future.
6.1. PDZ proteins
The carboxyterminal four amino acids of CFTR,
DTRL, form a binding site for the PDZ domains
(domain present in PSD-95, Dlg and ZO-1) of the
Na yH exchanger regulatory factor (NHE-RF; alsoq q
known as EBP50), a cytosolic protein concentrated at
the apical membrane of, for example, human airway
cells. The C-terminal part of NHE-RF (the ARM-
binding domain) binds ezrin, a protein kinase A anchor-
ing protein. CFTR immunoprecipitations from Calu3
cells contain PKA II activity and ezrin, and ezrin co-
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Fig. 4. CFTR and its interacting neighbors.
Fig. 5. Schematic representation of the different classes of CFTR mutations (modified from Moyer et al. w133x).
immunoprecipitates with the regulatory part of PKAII
w130x. Disruption of the interaction between protein
kinase A anchoring proteins and PKAII results in loss
of activation of CFTR by cAMP w131x. Therefore, NHE-
RF might serve as a bridging molecule that brings the
R-domain of CFTR in close proximity of protein kinase
A, hereby increasing the efficiency, selectivity and speed
of signal transduction w130,132x. Ezrin is also an actin
binding protein. In this way, the protein complex is
linked to the cytoskeleton and transduction of changes
in the cytoskeleton to the bound protein complex
becomes possible. Indeed, deletion of the last three
amino acids of CFTR gives rise to an equal distribution
of CFTR between the apical and the basolateral mem-
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branes while wildtype CFTR is predominantly found at
the apical membrane w133x. Substitution studies defined
the leucine at position 0 as the crucial amino acid for
polarized trafficking and both the leucine at position 0
and the threonine at position y2 are necessary for
efficient apical expression, chloride secretion and inter-
action with NHE-RF. These findings indicate that the
DTRL motif, and as a consequence the interactions
through PDZ domain containing proteins, is necessary
for polarized trafficking of the CFTR protein w134x.
NHE-RF contains two PDZ-domains that recognize
different C-terminal sequences: PDZ1 recognizes SyT-
RyY-L and PDZ2 recognizes S-SyT-W-L w135x. In this
way, PDZ-proteins can bind to multiple proteins and
give rise to a series of protein complexes as can be
found in the photoreceptor neurons of Drosophila w136x.
Physiological studies indicated that NHE-RF is able to
increase the P of CFTR channels in excised patches.o
However, both PDZ1 and PDZ2 have to be intact and
linked to each other in order to have an activating effect
on CFTR. This suggests that crosslinking of PDZ
domain binding proteins might be necessary. Increasing
evidence, however, indicates that one chloride channel
can be formed by two CFTR proteins and it is hypoth-
esized that NHE-RF might crosslink these two separate
CFTRs to form an active channel. Further research is
necessary to find out whether the activating, NHE-RF
binding factor is CFTR itself or another cellular com-
ponent w61x.
PDZ1 of NHE-RF is not only able to bind CFTR but
also the purinergic P2Y1 receptor and the b2 adrenergic
receptor. The physiological significance of this redun-
dancy is not clear yet w137x.
The last four amino acids of CFTR have a second
binding partner, CAP70 (CFTR-associated protein 70).
CAP70 contains 4 PDZ domains of which three bind to
the C-terminus of CFTR with different affinities. Bind-
ing of two CFTR molecules by one CAP molecule
results in the potentiation of the PKA and ATP activated
CFTR chloride current, indicating that CAP70 might
bring two CFTR molecules together to form one chloride
channel w63x.
The CFTR associated ligand CAL contains 1 PDZ
domain and binds also to the C-terminus of CFTR. This
protein is present in the golgi and plays a role in the
apical targeting of CFTR w138x.
6.2. AMP-activated protein kinase
Yeast two hybrid screens identified another binding
partner for the C-terminus of CFTR, the metabolic
sensor a1 AMP-activated protein kinase (AMPK).
AMPK is a serineythreonine kinase that responds to
changes in AMPyATP ratios by phosphorylating impor-
tant rate-limiting metabolic enzymes, and hereby inac-
tivating them, during conditions of, for example,
nutritional stress. Most CFTR expressing cells contain
also AMPK and both are localized at the apical
membrane. Since CFTR consumes ATP when activated,
AMPK might inactivate CFTR during periods of ATP
depletion. It was found that AMPK binds to the C-
terminal region of CFTR, encompassing amino acids
1420–1457, and is able to phosphorylate the chloride
channel. Co-expression of both proteins in oocytes
inactivates CFTR chloride transport. The reason for
CFTR phosphorylation and the residues involved remain
unknown. The region bound by AMPK contains tyrosine
1424, which forms part of an internalization signal that
is bound by the adaptor complex AP-2 during endocy-
tosis w52x. The interaction of CFTR with AMPK might
therefore interfere not only with the activity but also
with the trafficking of CFTR. This hypothesis remains,
however, unproven w139x.
6.3. SNARE proteins
Syntaxin 1A is a transmembrane SNARE-protein
present in the cell membrane of neurons, airway- and
gut epithelial cells. It inhibits the CFTR chloride channel
in two ways. First, it inhibits the cAMP-dependent
trafficking of CFTR to the cell membrane when co-
injected in Xenopus oocytes. The precise mechanism
that underlies this inhibition is not known w140x. Second,
it prevents the cAMP-dependent activation of CFTR
chloride transport w141x. For this, syntaxin 1A has to be
inserted in the cell membrane and its third helical
domain has to interact with acidic sequences located in
the N-terminal cytosolic tail of CFTR. These acidic
sequences bind also to the regulatory domain of the
CFTR protein. When the R domain is phosphorylated
by PKA, however, interaction of the R domain with
these N-terminal sequences is abolished w142x.
The N-terminal domain of CFTR is bound by two
other t-SNARE proteins, SNAP23 and SNAP25 that
form heterodimers with syntaxin 1A. They work coop-
eratively and all reduce the cAMP mediated chloride
current w143,144x. Their precise way of action remains
to be elucidated.
The R-domain of CFTR is also bound by SNARE
proteins. Yeast two hybrid screens identified syntaxin 8,
a t-SNARE, as a binding partner for the CFTR R
domain. Further investigation is needed to confirm this
and to unravel its function in CFTR maturation, degra-
dation, trafficking, activation or inactivation w145x. The
v-SNARE VAMP2 (synaptobrevin) binds also to the R-
domain and overexpression results in increased forskolin
induced short circuit currents and cell capacitance w144x.
Taken together, these results are consistent with the
involvement of the SNARE machinery in cAMP-regu-
lated CFTR trafficking. Moreover, the involvement of
the R-domain might indicate that phosphorylation-
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dependent interactions govern the CFTR insertion and
retrieval at the plasma membrane w144x
7. Classes of CFTR mutations
The cystic fibrosis transmembrane conductance regu-
lator is a multidomain protein characterized by a com-
plex regulation. As a result, nucleotide alterations in the
CFTR gene can disrupt CFTR function by different
mechanisms depending on their nature, and on the
domain in which these alterations occur. According to
these observations, CFTR mutations were subdivided by
Welsh and Smith w146x into four classes. This subdivi-
sion is still basically correct and straightforward. How-
ever, insight into CF-related phenotypes associated with
particular CFTR mutations w147x, and into the regulatory
properties of CFTR, on other ion channels w103x, has
made the extension of the number of classes to six (see
Fig. 5), and in the future possible to more.
7.1. Class I mutations
The first class of mutations includes nonsense muta-
tions, frame shift mutations and splice site mutations.
They give rise to the formation of premature termination
signals. As a consequence, unstable transcripts andyor
aberrant proteins containing deleted or novel amino acid
sequences might be formed. Such proteins are often
unstable and are expected to be degraded relatively
rapidly or to have little or no function. As a result, class
I mutations will cause loss of CFTR chloride channel
activity in the affected epithelia.
7.2. Class II mutations
The second class of mutations contains the majority
of the CF mutations, including the most frequent one
F508del, and is associated with improper maturation of
the corresponding CFTR proteins. During translation,
wildtype CFTR translation products are inserted into the
membrane of the endoplasmic reticulum and are core
glycosylated through addition of two high mannose
sugar groups on the fourth extracellular loop (Fig. 2).
Class II mutations give rise to a translation product that
is not able to attain the ‘wildtype’ properly folded
protease resistant structure in the ER. These immature
mutant proteins will remain associated with molecular
chaperones and will ultimately be ubiquinated and
degraded by the 26S proteasome present in the cytosol
w49x. As a consequence, these mutant proteins will not,
or only exceptionally, appear at the cell surface. The
amount of F508del CFTR that reaches the cell
membrane is tissue-specific w148x. These cell-specific
differences in quality control might be explained by
different levels of the Hsc70 co-chaperone CHIP that
targets immature CFTR proteins to the ubiquitin-protea-
some pathway w55x. However, rescued F508del CFTR
proteins show 5–20-fold accelerated degradation, when
compared to wildtype CFTR, in post-ER compartments,
most likely due to decreased conformational stability.
Therefore, differences in both the folding defects in the
ER and the instability of the rescued F508del CFTR
protein may contribute to the cell type-specific differ-
ences in accumulation of mutant CFTR at the cell
membrane. Both factors will have to be taken into
account when designing new therapies for the trafficking
defect of F508del CFTR w149x. How the degradation of
not F508del class II mutants occurs remains unknown.
Class II mutations are spread all over the CFTR
protein w87–90,150x. Mutagenesis of corresponding ami-
no acids located in the first and second nucleotide
binding domain may, however, have different effects on
the maturation of the corresponding protein: a defect in
maturation is more frequently observed when NBD1
amino acids are altered. This indicates that the folding
pattern of NBD1 itself, or of the surrounding sequences,
is very sensitive to mutational changes w151x. The C-
terminal tail contains amino acids that influence the
stability of the mature protein and mutations of these
amino acids tend to be classified as a new class of
mutations w152x.
7.3. Class III mutations
Wildtype CFTR channel activity is regulated by
phosphorylation of the R domain and binding and
hydrolysis of ATP at both nucleotide-binding domains.
Mutations that interfere with these processes are classi-
fied as class III. Most of these mutations are found in
the nucleotide binding domains and interfere with the
binding of ATP to these domains or with the stimulation
of the channel by ATP, resulting in a decrease of the
net chloride transport activity of the channel.
7.4. Class IV mutations
The fourth class of mutations affects amino acids
located in the pore of the channel and a CFTR channel
with defective conductive properties will be formed.
R117H, R334W and R234P all give rise to a chloride
channel with a normal phosphorylation and ATP-
dependent regulation, but with reduced single channel
currents. This class of mutations is in most cases
associated with a milder clinical phenotype w153x.
7.5. Class V mutations
Mutations located in the CFTR gene cannot only
result in cystic fibrosis but are also observed in patients
presenting only a partial CF phenotype like congenital
bilateral absence of the vas deferens (CBAVD) w154x,
obstructive azoospermia w155x, disseminated bronchiec-
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tasis w156,157x, allergic bronchopulmonary aspergillosis
w158x, hypertrypsinaemia w159x and chronic pancreatitis
w160x. Mutations associated with these diseases mostly
cause a decrease in the amount of CFTR proteins
produced. As a result, only the most ‘CFTR-needing’
organs will be affected w147x. These mutations often
affect splice sites; this is the case for the T5 polymor-
phism in intron 8 which affects the effectiveness with
which the intron 8 splice acceptor site is recognized
w154x and 3849q10 kb cyt which activates a cryptic
exon w161x. To some extent, normal splicing can still
occur in a small proportion of these transcripts and, as
a consequence, a small amount of functional CFTR
chloride channels will be generated, resulting in a mild
phenotype.
Mutations that cause a small defect in maturation but
normal or increased chloride transport activity, like
A455E and P574H tend to be classified in this fifth
class of mutations w162x.
7.6. Class VI mutations
CFTR does not only function as a chloride channel,
but also exhibits regulatory properties towards other ion
channels like ENaC, ORCC, « A sixth class of muta-
tions harbors nucleotide alterations that affect the regu-
latory properties of the CFTR protein. Sugita et al. w108x
pointed out that a CFTR protein with a functional R
domain is required to activate an ATP channel associated
with CFTR. Moreover, different parts of the CFTR
protein are needed to function as a chloride transporter
or as a regulator of other proteins: expression of a
truncated CFTR protein containing only the first trans-
membrane domain is already sufficient to produce a
chloride channel that is constitutively active but the
presence of the first nucleotide binding domain and the
regulatory domain is necessary to regulate the activity
of ORCC w85x. Mutational analysis showed that two
CFTR mutations resulting in CFTR channels with
reduced chloride transport, A455E and G551D, have a
different impact on the regulation of ORCC: A455E
retains its ability to stimulate ORCC and G551D not
w103x.
Some mutations, however, will disrupt the normal
functioning of the CFTR protein in more than one way,
and will therefore have to be catalogued in different
mutation classes. For example, F508del, the most fre-
quent CFTR mutation, causes an arrest in maturation
(class II) and down-regulates the activity of the F508del
chloride channel (class III).
8. The future: a cure for cystic fibrosis?
A better understanding of the underlying defects that
cause cystic fibrosis has led to the development of new
treatments that will increase the quality of life, and the
lifespan, of CF-patients. Therapies like digestion enzyme
supplements that circumvent the malfunctioning of the
pancreas, antibiotics to treat lung infections and human
recombinant DNase to solubilize the mucus in the lung,
are symptomatic treatments for CF but do not correct
the primary defect.
The most life-threatening feature of cystic fibrosis is
malfunctioning of the excretory epithelium. A cure that
could abolish the deterioration of lung function, by
breaking the viscous circle in which the lung epithelium
seems to be caught once the first bacterial colonization
is established, would have a great impact on the quality
of life and the life expectancy of CF-patients. In the
lung of non-affected humans, a non-selective defense
mechanism, composed of antimicrobial factors like
defensins and lysozyme forms the primary barrier
against pathogens. In CF-patients, this defense mecha-
nism is inactivated by the altered composition of the
airway surface fluid w32x. Reconstitution of this primary
defense in CF-patients could be a first step in the
prevention of lung disease, and as a consequence, in the
prevention of deterioration of lung function. The acti-
vation of other chloride channels present in lung epithe-
lial cells, or addition of wildtype CFTR genes or proteins
can also be considered. Protein replacement therapy has
been tested in vitro w163x and in vivo in nasal epithelia
of CFTR knockout mice w164x. Although functional
proteins, incorporated in liposomes, could be delivered
to the epithelial cells, the incorporation of functional
chloride channels in the cell membrane remained inef-
ficient. Gene therapy trials using liposomes, adenovirus-
es, adeno associated and other viruses are in progress.
Although they are all able to deliver the CFTR coding
sequence to the cells under study, the resulting expres-
sion levels are too low and viral vectors, in particular
adenoviruses, induce severe immune responses when
administered multiple times. Moreover, the question
remains which cells in the lung epithelium need to be
corrected and to what extent w165x. The CFTR protein
is not only active in the cell membrane but also on
intracellular membranes. In the Golgi-stacks, CFTR
ensures the presence of an optimal pH for the different
glycosylation processes. As a consequence, in CF cells,
the glycosylation processes in the Golgi-stacks are
abnormal and glycoproteins with enhanced sulfation and
decreased sialylation are produced. This leads to a better
adherence of Pseudomonas aeruginosa, a CF epithelia
colonizing bacteria and as a result, promotes lung
infections. When CFTR genes were administrated to
human bronchial CF xenografts, correction of the two
phenotypes, transepithelial chloride transport and gly-
cosylation of proteins, was dependent on the CFTR
expression pattern obtained. Cells treated with CFTR-
liposomes showed a low CFTR expression level and
transepithelial chloride transport but showed a correction
of protein sulfation processes. When adenoviruses con-
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taining the CFTR coding region were used, the opposite
was found: the expression level was high, chloride
transport was normalized but protein sulfation was still
abnormal. This indicates that different expression levels
are required to correct different aspects of the CF
phenotype, a feature that has to be taken into account
when designing and analyzing gene therapy trials in the
future w166x.
Another feature of cystic fibrosis in humans and
CFTR knockout mice is a defect in fatty acid metabo-
lism: the amount of phospholipid-bound arachidonic
acid is increased and the amount of phospholipid-bound
docosahexaenoic acid (DHA) is decreased. Oral admin-
istration of DHA to CFTR knockout mice corrected not
only the lipid imbalance but also the pathological man-
ifestations w167x. This observation might form a new
start point in the search for a better treatment of cystic
fibrosis.
An increasing insight into the way in which specific
mutations cause malfunctioning of the chloride channel
has also opened new prospects in the search for new
treatments. Nonsense mutations account for 5% of
mutant CFTR chromosomes. Aminoglycosides, like
G418 and gentamicin, can result in readthrough of these
premature stop codons, in vitro, and give rise to the
appearance of full-length CFTR mRNA w166–169x. The
in vivo usefulness of gentamicin is currently being tested
in phase I clinical trials.
F508del CFTR is a class II mutation that retains some
chloride transport activity if it escapes from the ER
control system and reaches the cell membrane. Incubat-
ing F508del cells at lower temperature (26 8C) w170x or
in the presence of chemical chaperones like glycerol
(5%) w171x, trimethylamine N-oxide or deuterated water
w172x, causes an increase in the amount of mutant CFTR
proteins that reaches the cell membrane in vitro. These
techniques are, however, not applicable in vivo. Treat-
ment of these cells with sodium butyrate induces over-
expression of F508del CFTR and results also in the
appearance of mutant but still partially functional chlo-
ride channels in the cell membrane w173x. This approach
is useful in vivo to treat class II mutations and phase I
clinical trials are under way for phenylbutyrate, a buty-
rate analogue that has been developed to treat urea cycle
disorders w174x.
Class III mutations interfere with the cAMP- and
ATP-dependent activation of CFTR chloride channels.
A search for compounds that normalize this defect has
identified three potential agents: the phosphodiesterase
inhibitor milrinone, the protein phosphatase inhibitor
genistein and the xanthine A1-adenosine receptor agonist
8-cyclophenyl-1,3-dipropylxanthine (CPX) that specifi-
cally activates the F508del channel and for which a
phase I trial has been set up w174x.
From the given examples, it seems that particular
treatments for specific mutations might become available
in the future. Knowledge of the underlying mechanism
by which specific mutations cause malfunctioning of the
CFTR chloride channel, will, however, be indispensable
to fully correct these defects.
9. Conclusion
The cystic fibrosis transmembrane conductance regu-
lator has not stolen its name. It is a multidomain protein
that is characterized by a complex regulation, both at
the expression and at the activation level, and has been
associated with multiple functions. During the past
years, many interacting proteins have been identified.
The part they play in the cause and in the progression
of cystic fibrosis remains generally unresolved. The
information that will emerge during the next years will
most probably open new ways for the development of
therapies. Moreover, the identification of genes that are
involved in the progression of the pulmonary disease
can lead to a cure that, together or complementary with
the optimalization of gene therapy and protein therapy,
improves, or cures the most life threatening aspect of
cystic fibrosis disease, the detoriation of lung function.
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